ibritumomab tiuxetan

Ligand id: 6777

Name: ibritumomab tiuxetan

No information available.
Summary of Clinical Use
Used to treat relapsed or refractory, low grade or transformed B cell non-Hodgkin's lymphoma (labelled with the high energy beta emitter, Yttrium-90). Can be labelled with Indium-111 for diagnostic investigation/imaging.
Mechanism Of Action and Pharmacodynamic Effects
Yttrium-90 conjugated anti-CD20 monoclonal antibody. Once bound to CD-20 +ve B-cells of the lymphoma, the beta particles act locally to destroy the cancerous cells.
External links